Hypotension in heart failure is less harmful if associated with high or increasing doses of heart failure medication: Insights from the Swedish Heart Failure Registry.

Publisher: Wiley Country of Publication: England NLM ID: 100887595 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1879-0844 (Electronic) Linking ISSN: 13889842 NLM ISO Abbreviation: Eur J Heart Fail Subsets: MEDLINE

Publication: 2014- : Chichester : Wiley
Original Publication: Amsterdam ; New York : Elsevier Science, c1999-

Heart Failure*/drug therapy ; Heart Failure*/epidemiology ; Hypotension*/chemically induced ; Hypotension*/epidemiology ; Hypotension*/drug therapy; Humans ; Aged ; Sweden/epidemiology ; Stroke Volume/physiology ; Antihypertensive Agents ; Adrenergic beta-Antagonists/therapeutic use ; Registries

Aims: Heart failure (HF) medication may reduce blood pressure (BP). Low BP is associated with worse outcomes but how this association is modified by HF medication has not been studied. We evaluated the association between BP and outcomes according to HF medication dose in HF with reduced ejection fraction (HFrEF).
Methods and Results: We studied HFrEF patients from the Swedish HF registry (2000-2018). Associations between systolic BP (SBP) and cardiovascular death (CVD) and/or HF hospitalization (HFH) were analysed according to doses of renin-angiotensin system (RAS) inhibitors, beta-blockers and mineralocorticoid receptor antagonists (MRA). Among 42 040 patients (median age 74.0), lower baseline SBP was associated with higher risk of CVD/HFH (adjusted hazard ratio [HR] per 10 mmHg higher SBP: 0.92, 95% confidence interval [CI] 0.92-0.93), which was less high risk under optimized RAS inhibitor and beta-blocker doses (10% decrease in event rates per 10 mmHg SBP increase in untreated patients vs. 7% decrease in patients at maximum dose, both adjusted p < 0.02). Among the 13 761 patients with repeated measurements, 9.9% reported a SBP decrease >10 mmHg when HF medication doses were increased, whereas 24.6% reported a SBP decrease >10 mmHg with stable/decreasing doses. Decreasing SBP was associated with higher risk of CVD/HFH in patients with stable (HR 1.10, 95% CI 1.04-1.17) or decreasing (HR 1.29, 95% CI 1.18-1.42) HF medication dose but not in patients with an increase in doses (HR 0.94, 95% CI 0.86-1.02).
Conclusions: The association of lower SBP with higher risk of CVD/HFH is attenuated in patients with optimized HF medication. These results suggest that low or declining SBP should not limit HF medication optimization.
(© 2023 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.)

Thorvaldsen T, Benson L, Dahlstrom U, Edner M, Lund LH. Use of evidence‐based therapy and survival in heart failure in Sweden 2003‐2012. Eur J Heart Fail 2016;18:503–511. https://doi.org/10.1002/ejhf.496.
Lund LH. Increasing complexity of heart failure therapy requires earlier and more frequent referral. J Card Fail 2019;25:317–318. https://doi.org/10.1016/j.cardfail.2019.04.015.
Komajda M, Anker SD, Cowie MR, Filippatos GS, Mengelle B, Ponikowski P, et al.; QUALIFY Investigators. Physicians' adherence to guideline‐recommended medications in heart failure with reduced ejection fraction: Data from the QUALIFY global survey. Eur J Heart Fail 2016;18:514–522. https://doi.org/10.1002/ejhf.510.
Maggioni AP, Anker SD, Dahlström U, Filippatos G, Ponikowski P, Zannad F, et al.; Heart Failure Association of the ESC (HFA). Are hospitalized or ambulatory patients with heart failure treated in accordance with European Society of Cardiology guidelines? Evidence from 12,440 patients of the ESC Heart Failure Long‐Term Registry. Eur J Heart Fail 2013;15:1173–1184. https://doi.org/10.1093/eurjhf/hft134.
Rossignol P, Lainscak M, Crespo‐Leiro MG, Laroche C, Piepoli MF, Filippatos G, et al.; Heart Failure Long‐Term Registry Investigators Group. Unravelling the interplay between hyperkalaemia, renin‐angiotensin‐aldosterone inhibitor use and clinical outcomes. Data from 9222 chronic heart failure patients of the ESC‐HFA‐EORP Heart Failure Long‐Term Registry. Eur J Heart Fail 2020;22:1378–1389. https://doi.org/10.1002/ejhf.1793.
Schmid FA, Schlager O, Keller P, Seifert B, Huang R, Fröhlich GM, et al. Prognostic value of long‐term blood pressure changes in patients with chronic heart failure. Eur J Heart Fail 2017;19:837–842. https://doi.org/10.1002/ejhf.805.
Thorvaldsen T, Benson L, Ståhlberg M, Dahlström U, Edner M, Lund LH. Triage of patients with moderate to severe heart failure: Who should be referred to a heart failure center? J Am Coll Cardiol 2014;63:661–671. https://doi.org/10.1016/j.jacc.2013.10.017.
Anand IS, Rector TS, Kuskowski M, Thomas S, Holwerda NJ, Cohn JN. Effect of baseline and changes in systolic blood pressure over time on the effectiveness of valsartan in the Valsartan Heart Failure Trial. Circ Heart Fail 2008;1:34–42. https://doi.org/10.1161/CIRCHEARTFAILURE.107.736975.
Ivanovic B, Tadic M. When does low normal blood pressure become too low? The J‐curve phenomenon. Acta Cardiol 2014;69:121–129. https://doi.org/10.2143/AC.69.2.3017292.
Ettehad D, Emdin CA, Kiran A, Anderson SG, Callender T, Emberson J, et al. Blood pressure lowering for prevention of cardiovascular disease and death: A systematic review and meta‐analysis. Lancet 2016;387:957–967. https://doi.org/10.1016/S0140‐6736(15)01225‐8.
Cautela J, Tartiere JM, Cohen‐Solal A, Bellemain‐Appaix A, Theron A, Tibi T, et al. Management of low blood pressure in ambulatory heart failure with reduced ejection fraction patients. Eur J Heart Fail 2020;22:1357–1365. https://doi.org/10.1002/ejhf.1835.
Savarese G, Vasko P, Jonsson A, Edner M, Dahlström U, Lund LH. The Swedish Heart Failure Registry: A living, ongoing quality assurance and research in heart failure. Ups J Med Sci 2019;124:65–69. https://doi.org/10.1080/03009734.2018.1490831.
Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JG, Coats AJ, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail 2016;18:891–975. https://doi.org/10.1002/ejhf.592.
McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Böhm M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). With the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail 2022;24:4–131. https://doi.org/10.1002/ejhf.2333.
Buuren S, Groothuis‐Oudshoorn C. MICE: Multivariate imputation by chained equations in R. J Stat Softw 2011;45:45. https://doi.org/10.18637/jss.v045.i03.
Gheorghiade M, Abraham WT, Albert NM, Greenberg BH, O'Connor CM, She L, et al.; OPTIMIZE‐HF Investigators and Coordinators. Systolic blood pressure at admission, clinical characteristics, and outcomes in patients hospitalized with acute heart failure. JAMA 2006;296:2217–2226. https://doi.org/10.1001/jama.296.18.2217.
Raphael CE, Whinnett ZI, Davies JE, Fontana M, Ferenczi EA, Manisty CH, et al. Quantifying the paradoxical effect of higher systolic blood pressure on mortality in chronic heart failure. Heart 2009;95:56–62. https://doi.org/10.1136/hrt.2007.134973.
Lam CSP, Arnott C, Beale AL, Chandramouli C, Hilfiker‐Kleiner D, Kaye DM, et al. Sex differences in heart failure. Eur Heart J 2019;40:3859–3868c. https://doi.org/10.1093/eurheartj/ehz835.
Jonsson A, Norberg H, Bergdahl E, Lindmark K. Obstacles to mineralocorticoid receptor antagonists in a community‐based heart failure population. Cardiovasc Ther 2018;36:e12459. https://doi.org/10.1111/1755‐5922.12459.
Bozkurt B. Response to Ryan and Parwani: Heart failure patients with low blood pressure: How should we manage neurohormonal blocking drugs? Circ Heart Fail 2012;5:820–821. https://doi.org/10.1161/CIRCHEARTFAILURE.112.972240.
Rossignol P, Girerd N, Gregory D, Massaro J, Konstam MA, Zannad F. Increased visit‐to‐visit blood pressure variability is associated with worse cardiovascular outcomes in low ejection fraction heart failure patients: Insights from the HEAAL study. Int J Cardiol 2015;187:183–189. https://doi.org/10.1016/j.ijcard.2015.03.169.
Ferreira JP, Duarte K, Pitt B, Dickstein K, McMurray JJV, Zannad F, et al. Visit‐to‐visit blood pressure variation is associated with outcomes in a U‐shaped fashion in patients with myocardial infarction complicated with systolic dysfunction and/or heart failure: Findings from the EPHESUS and OPTIMAAL trials. J Hypertens 2018;36:1736–1742. https://doi.org/10.1097/hjh.0000000000001742.
Monzo L, Ferreira JP, Abreu P, Szumski A, Böhm M, McMurray JJV, et al. Visit‐to‐visit blood pressure variation and outcomes in heart failure with reduced ejection fraction: Findings from the Eplerenone in Patients with Systolic Heart Failure and Mild Symptoms trial. J Hypertens 2020;38:420–425. https://doi.org/10.1097/HJH.0000000000002275.
Mancia G. Visit‐to‐visit blood pressure variability: An insight into the mechanisms. Hypertension 2016;68:32–33. https://doi.org/10.1161/HYPERTENSIONAHA.116.07139.

Keywords: Blood pressure; Cardiovascular diseases; Dose; Heart failure; Heart failure with reduced ejection fraction; Medication

0 (Antihypertensive Agents)
0 (Adrenergic beta-Antagonists)

Date Created: 20231026 Date Completed: 20240327 Latest Revision: 20240327

20240327

10.1002/ejhf.3066

37882142